Modern medicine and the pharmaceutical industry have achieved great success over the past century, extending human life expectancy and burying fatal diseases in history. However, today, the healthcare sector is experiencing a dangerous axis shift between its primary goal of "protecting and improving human health" and its obligation to "maximize profit" for its shareholders. This corruption is not accidental; it is a natural, yet equally devastating, consequence of the economic incentives upon which the system is built.

Chronic Diseases and the "Sustainable" Customer Model The biggest revenue stream for the pharmaceutical industry is not one-time treatments that completely cure the patient, but drugs for chronic diseases that the patient must use for a lifetime. While a vaccine or gene therapy that eradicates a disease at its root is a medical miracle, it does not offer a financially sustainable model.

Indeed, the question "Is curing patients a sustainable business model?" explicitly asked in a 2018 report prepared by the financial giant Goldman Sachs for biotechnology investors, summarizes the gravity of the situation. The report stated that one-time treatments cut off long-term profit flows. The cold and ruthless business rule of the sector is this: A cured patient is a lost customer. Therefore, massive investments are directed not at ending the disease, but at drugs that will make the patient dependent on the system for life by suppressing the symptoms of conditions such as hypertension, cholesterol, diabetes, or depression.

The R&D Myth and the Reality The most frequently used argument when defending the high cost of drugs is "Billions of dollars in R&D (Research and Development) costs and long testing processes." But how much of these costs is actually spent on innovative treatments?

Data shows that the reality is quite different. Many of the world's largest pharmaceutical companies allocate much larger budgets to marketing, advertising, and lobbying activities than to R&D. Furthermore, a significant portion of the "new" drugs introduced to the market are actually "me-too" drugs, which contain no new molecular discoveries but feature minor formula changes to extend the patent life of existing drugs. In addition, many groundbreaking basic medical researches are initially conducted in state-supported universities with public funds (taxpayers' money); when a molecule shows promise, it is bought and commercialized by companies. There is a risk involved, but this risk is not as one-sided as the companies claim.

Intervening at the Source of the Prescription: The "Rep-ification" of Physicians The most strategic targets of the companies' massive marketing budgets are not the patients directly, but the physicians, who are the gatekeepers of the system. The fate of a drug in the market is determined by the preferences of the doctor who prescribes it. At this point, pharmaceutical companies closely mark physicians with sponsored congresses, "consulting" fees, research grants, free samples, and constant office visits.

This intense attention and direction can erode ethical boundaries over time, transforming the physician from an independent healthcare professional into a "voluntary representative" of a specific company, whether they realize it or not. For instance, data revealed through transparency laws like the Sunshine Act (Open Payments Database) in the US has proven a striking fact: Doctors who receive financial support, meals, or gifts from pharmaceutical companies have a statistically much higher tendency to prescribe the specific drugs produced by those companies—which are usually much more expensive than their generic counterparts. This state of "being incentivized" creates the risk that the patient receives not the objectively best treatment, but the most aggressively marketed one.

Patent Monopoly and Price Manipulation When a pharmaceutical company develops a new drug, it typically gains a 20-year patent right. This is the right to be the sole legal seller of that drug during that period, meaning a monopoly.

This is the point where free-market rules fail to operate in healthcare. A patient does not have the luxury of rejecting a life-saving drug by saying, "The price is too high, I won't buy it." This desperation gives companies the power to manipulate the price of the drug as they wish. The most striking example of this is when Martin Shkreli (Turing Pharmaceuticals) in the US bought the patent for a 60-year-old drug called Daraprim, used by HIV patients, and raised its price from $13.5 to $750 (more than 5000%) overnight. Likewise, the fact that even the price of insulin, whose formula was discovered decades ago, is constantly increased under the monopoly of certain companies is the clearest indicator of how greed for profit holds human life hostage.

The Systematic Suppression of Preventive Medicine The darkest side of this entire equation is the treatment of the concept of "Preventive Medicine." Preventive medicine aims to prevent disease at the cellular level before it even occurs through proper nutrition, avoiding toxins, stress management, and an active lifestyle.

However, the current healthcare industry has no motivation to invest in or promote preventive medicine. Because a healthy diet, a good night's sleep, or exercise cannot be patented. People not getting sick means massive hospital chains, high-tech imaging device manufacturers, and billion-dollar pharmaceutical companies will lose money. The system is designed to make money not from "health," but from "disease management." That is why education on nutrition and lifestyle changes in medical schools is almost non-existent, while there is a drug prescription ready to be written for every symptom.

Conclusion As a result; it is not rational to reject the modern medical system entirely; the successes of modern medicine in emergency interventions, surgery, and infectious diseases are indisputable. However, in the management of chronic diseases and the determination of health policies, this hegemony established by profit-oriented companies over human health is no longer sustainable. Correcting this axis shift—where human life is transformed into a commercial commodity, patients into lifetime subscriber customers, and physicians into sales representatives—is not only a medical necessity but also a legal, moral, and systemic one.